Effectiveness of an AI-Enabled Mobile Intervention on Lifestyle Behaviors and Maternal-Infant Health
Effects of an AI-driven Mobile Health Management Intervention to Prevent Gestational Diabetes Mellitus in High-risk Pregnant Women: A Pragmatic Randomized Controlled Trial
The goal of this pragmatic randomized controlled trial is to evaluate the effectiveness of an AI-enabled mobile health management application ("Better Pregnancy" app), grounded in the Theory of Planned Behavior, in preventing gestational diabetes mellitus (GDM) among pregnant women at high risk of GDM, and to assess its impact on maternal and infant health outcomes.
Study Population: Eligible participants are pregnant women aged 18-49 years, with a singleton pregnancy, gestational age <12 weeks at enrollment, and at least one GDM risk factor (age ≥35 years, pre-pregnancy BMI ≥24 kg/m², family history of diabetes, previous history of GDM, prior delivery of a macrosomic infant [birth weight ≥4000 g], or polycystic ovary syndrome). Participants must have no heart, liver, or kidney diseases, use an Android smartphone, and provide written informed consent.
The main questions it aims to answer are:
Can the AI-driven mobile lifestyle intervention reduce the incidence of GDM in high-risk pregnant women?
Does the intervention improve lifestyle behaviors (diet, physical activity, sleep) and glycemic control (measured by continuous glucose monitoring) in participants?
What is the adherence, acceptability, and cost-effectiveness of this intervention in real-world clinical settings?
Comparison: Researchers will compare two groups of pregnant women: the intervention group (receiving the AI-enabled "Better Pregnancy" app plus routine antenatal care) and the control group (receiving routine antenatal care alone).
Participants will:
Enroll in the first trimester (<12 weeks of gestation) and complete a baseline lifestyle and health status questionnaire
In the intervention group: watch 7 cognitive-attitudinal videos within the first week, then complete 12 weeks of AI-driven personalized intervention (daily check-ins, receiving tailored recommendations on diet, physical activity, sleep, etc.)
During the intervention period, participants in the intervention group will wear a continuous glucose monitoring device for 7 days to assess the impact of the intervention on glycemic fluctuations
Complete the first follow-up lifestyle and health status assessment after the intervention (approximately in the second trimester)
Undergo an oral glucose tolerance test during the second trimester (24-28 weeks)
Complete the second follow-up lifestyle and health status assessment in the third trimester (≥28 weeks)
Complete the third follow-up lifestyle and health status assessment at 42 days postpartum, along with collection of delivery outcomes and infant health information
A subset of participants may voluntarily provide blood and stool samples for mechanistic studies
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Fangbiao Tao, PhD
- 電話番号：13856986775
- メール：taofangbiao@126.com
研究連絡先のバックアップ
- 名前：Tiemei Li, PhD
- 電話番号：13541602092
- メール：tiemei.li@foxmail.com
研究場所
-
-
Anhui
-
Hefei、Anhui、中国、231200
- Anhui Medical University
-
コンタクト：
- Tiemei Li, PhD
- 電話番号：13541602092
- メール：tiemei.li@foxmail.com
-
コンタクト：
-
主任研究者：
- Tiemei Li, PhD
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Pregnant women aged ≥18 years
- Singleton pregnancy
- Gestational age <13+6 weeks at enrollment
At least one of the following GDM risk factors:
- Age ≥35 years
- Pre-pregnancy BMI ≥24 kg/m²
- Family history of diabetes (first-degree relatives)
- Previous history of gestational diabetes mellitus
- Prior delivery of a macrosomic infant (birth weight ≥4000 g)
- Polycystic ovary syndrome
- Use of an Android smartphone
- No severe heart, liver, or kidney diseases
- Voluntary participation and signed informed consent
Exclusion Criteria:
- Pre-pregnancy diagnosis of diabetes mellitus (type 1 or type 2)
- Severe mental illness
- Confirmed severe pregnancy complications (e.g., preeclampsia, placental abruption, etc.)
- Inability to complete questionnaires or intervention
- Participation in other interventional studies
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Intervention Group: AI-Enabled Mobile Health Management App Plus Routine Antenatal Care
Participants receive a 12-week AI-powered intervention via the "PregSelfCare" app plus routine antenatal care.
The intervention includes: (1) watching 7 theory-based videos and completing an attitude questionnaire in week 1; (2) daily check-in (mood, water, fruit, bowel movements, sunlight, weight) and receiving AI-driven personalized recommendations (diet photo feedback, step goals, sleep advice, emotion-relief videos, supplement reminders) during weeks 1-12, with content dynamically adjusted based on baseline lifestyle assessment and adherence; (3) wearing a continuous glucose monitor for 7 days; (4) completing a satisfaction questionnaire after the intervention (week 12), with a subset invited for semi-structured interviews.
|
Participants receive a 12-week AI-powered intervention via the "PregSelfCare" app plus routine antenatal care.
The intervention includes: (1) watching 7 theory-based videos and completing an attitude questionnaire in week 1; (2) daily check-ins (mood, water, fruit, bowel movements, sunlight, weight) and receiving AI-driven personalized recommendations (diet photo feedback, step goals, sleep advice, emotion-relief videos, supplement reminders) during weeks 1-12, with content dynamically adjusted based on baseline lifestyle assessment and adherence; (3) wearing a continuous glucose monitor for 7 days; (4) completing a satisfaction questionnaire after the intervention (week 12), with a subset invited for semi-structured interviews.
|
|
介入なし：Control Group: Routine Antenatal Care Alone
Participants in the control group receive routine antenatal care and standardized pregnancy health education (including verbal guidance and conventional brochures) provided by their hospitals.
They do not have access to the "Better Pregnancy" app and receive no additional mobile health intervention.
Data collection, including questionnaires and oral glucose tolerance tests, is completed at the same time points as the intervention group.
After study completion, control participants will be offered access to the app.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The prevalence of gestational diabetes mellitus
時間枠：24 Weeks
|
The diagnostic criteria for Potential simultaneous submissions were found in: International Journal of Nursing Sciences will follow the International Association of Diabetes and Pregnancy Study Groups (IADPSG) guidelines.
Glucose tolerance tests will be conducted at 24 weeks of gestation (calculated from the last menstrual period).
According to the diagnostic criteria, reference values for fasting, one-hour, and two-hour blood glucose levels are 5.1 mmol/L, 10.0 mmol/L, and 8.5 mmol/L, respectively.
A diagnosis of gestational diabetes mellitus is confirmed if any of these values meet or exceed the specified thresholds
|
24 Weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse pregnancy and adverse birth outcomes
時間枠：42 days postpartum
|
Maternal pregnancy outcomes and general neonatal outcomes were collected via self administered scales
|
42 days postpartum
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。